|
|
|
|
|
|
Free Newsletters
Archive
My eNewsletters
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Login
Become a Member
Discussion Forums
FAQ
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Career Definitions
Labor Market Reports
Education & Training
Regions
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
Arizona State University's Biodesign Institute and ImmuneRegen BioSciences, Inc. (IRBO) Collaborate to Investigate Possible Enhancement of Vaccine Against Norwalk Viruses
8/18/2008
SCOTTSDALE, AZ--(Marketwire - August 18, 2008) - ImmuneRegen® BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBS), today announced a collaborative relationship with the Biodesign Institute at Arizona State University (ASU), Tempe, Ariz., to evaluate the effectiveness of ImmuneRegen's Viprovex® in boosting the immune response when used as an adjuvant in conjunction with unique plant-derived vaccines against noroviruses (also called Norwalk-like viruses). These viruses are the leading cause of gastrointestinal illness throughout the world, and are often at the root of outbreaks in closed living communities such as nursing homes, cruise ships or prisons. Demonstrating successful adjuvant activity could increase the effectiveness of immunizations, thereby reducing cost per dose and increasing vaccine availability.
|
|
|
|
|
|
|
|
|
|
|
|